Clinical Trial Update: Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating radiotherapy in combination with tislelizumab and anlotinib for hepatocellular carcinoma with portal vein tumor thrombus;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Portal Vein Tumor Thrombosis

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: HCC - Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING